Advertisement
Document › Details
Neurimmune AG. (4/26/18). "Press Release: Neurimmune Appoints Fabian Buller as Chief Business Officer". Schlieren.
Organisation | Neurimmune AG | |
Organisation 2 | Covagen AG | |
Group | Johnson & Johnson (JnJ) (Group) | |
Product | therapeutic antibody | |
Product 2 | human antibody, therapeutic | |
Person | Buller, Fabian (Neurimmune 201804– CBO before JnJ Innovation + Covagen) | |
Person 2 | Nitsch, Roger M. (Neurimmune 201809 CEO + Co-Founder + Evotec Biosystems 199906 Scientific Advisory Board) | |
Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has appointed Dr. Fabian Buller to the newly created position Chief Business Officer. As an experienced biotech executive, Dr. Buller joins Neurimmune’s executive team and brings 8 years of professional experience with biotech and pharma companies.
“Neurimmune develops novel treatments for human diseases with high unmet medical needs. Our pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages, including molecules that are developed in collaboration with leading pharmaceutical companies”, said Roger Nitsch, President & CEO of Neurimmune. “Following our recent raise of $150 million, we are pleased that Dr. Buller joins our company to further drive our growth strategy. Dr. Buller has an impressive track record in business development and licensing transactions. He will play a key role in realizing opportunities that will allow us to bring novel therapeutics to patients.”
Prior to joining Neurimmune, Dr. Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. He was instrumental in securing a number of major Biotech-Pharma deals including the sale of Covagen to J&J. Dr. Buller holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.
About Neurimmune
Neurimmune is a biopharmaceutical company dedicated to the development of human-derived therapeutic antibodies for the treatment and prevention of human diseases with a high unmet medical need. Established in 2006, Neurimmune has rapidly grown into a leader in the field of recombinant human monoclonal antibody therapeutics. Neurimmune’s pipeline comprises high-potential drug candidates at both clinical and advanced preclinical development stages. Aducanumab, an investigational treatment for Alzheimer’s disease, partnered with Biogen, is currently in phase 3 clinical trials. Rights in antibodies BIIB054 for Parkinson’s disease and BIIB076 for Alzheimer’s disease were acquired by Biogen. In 2016, Neurimmune partnered with TVM and Eli Lilly’s Chorus unit to advance an antibody for the treatment of amyotrophic lateral sclerosis. In 2017, Neurimmune entered into a collaboration with Ono Pharmaceutical in Japan. Neurimmune’s pipeline includes human antibody programs for cardiomyopathy, type-2 diabetes and progressive multifocal leukoencephalopathy, with potential therapies in advanced preclinical stages.
Record changed: 2023-06-05 |
Advertisement
More documents for Neurimmune AG
- [1] Neurimmune AG. (1/17/22). "Press Release: Neurimmune Expands Drug Discovery Collaboration with Ono Pharmaceutical in the Field of Neurodegenerative Diseases". Zürich....
- [2] Neurimmune AG. (1/7/22). "Press Release: Neurimmune Enters into a Collaboration and License Agreement with AstraZeneca to Develop and Commercialize NI006". Zürich....
- [3] Neurimmune AG. (4/1/20). "Press Release: Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of Covid-19". Zurich & Munich....
- [4] Neurimmune AG. (3/1/19). "Press Release: Neurimmune Appoints John Dellapa as General Counsel". Schlieren....
- [5] Neurimmune AG. (11/1/18). "Press Release: Neurimmune Appoints Natascha Schill as VP Project and Alliance Management". Schlieren....
- [6] Neurimmune AG. (9/18/18). "Press Release: Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical". Schlieren....
- [7] Neurimmune AG. (9/12/18). "Press Release: Neurimmune Appoints Christoph Hock as Chief Medical Officer to Lead Clinical Development". Schlieren....
- [8] Neurimmune AG. (5/1/18). "Press Release: Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab". Cambridge, MA & Schlieren....
- [9] Neurimmune AG. (11/9/17). "Press Release: Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top